Research conducted by Stanford University and published in Science Translational Medicine shows successful injection of protein formulations exceeding 500 mg/mL
PALO ALTO, Calif., Aug. 20, 2025 /PRNewswire/ — Surf Bio, a biopharmaceutical company transforming the delivery of antibodies and biologics, announced today that a peer-reviewed study conducted by researchers at Stanford University and published in Science Translational Medicine has demonstrated the feasibility of reformulating biologics for subcutaneous delivery at ultra-high concentrations. The study’s lead author, Carolyn Jons, Ph.D., and collaborators reported that spray-dried microparticle formulations surpassed 500 mg/mL and were delivered through a standard 27-gauge needle at clinically relevant forces, marking a potential breakthrough in expanding access to infusion-only therapies.
The paper, entitled, “Glassy Surfactants Enable Ultra-High Concentration Biologic Therapeutics,” may be accessed via the following URL: https://www.doi.org/10.1126/scitranslmed.adv6427
“The research addresses one of the most persistent challenges in drug delivery: how to administer high-dose biologic therapies without the need for intravenous infusion,” stated Dr. Jons. “Many existing protein-based therapies require hospital or clinic-based infusions due to their large volume, instability, or reconstitution requirements. This study describes a spray-drying process that converts protein formulations into microparticles suspended in a non-solvent liquid carrier, resulting in a stable, ready-to-inject solution that meets the viscosity and force thresholds for subcutaneous administration.”
“This research provides a critical foundation for our work at Surf Bio and highlights the significant potential of our SnapShot™ technology,” said Bryan Mazlish, CEO of Surf Bio. “We’re leveraging this licensed platform to help unlock subcutaneous administration for therapies that have historically required IV infusion. Our goal is to translate this innovation into ready-to-inject, patient-friendly formulations that reduce burden on the healthcare system while enabling self-administration at home.”
Importantly, the platform utilizes a polymer excipient that improves stability during spray drying and enhances the injectability of the final formulation. In preclinical models, these microparticles were shown to maintain protein activity and structure, achieving doses well beyond those currently accessible with drug products approved for subcutaneous delivery. The technology does not require any specialized delivery device and can be used with commercially available autoinjectors and standard fill-finish processes.
About Surf Bio:Surf Bio is a biopharmaceutical company transforming the delivery of antibodies and biologics via its SnapShot™ technology platform. Powered by the Company’s proprietary polymer, SnapShot enables the development of ultra-high concentration formulations of monoclonal antibodies (mAbs) and biologics that can be administered using a single, standard autoinjector shot. To date, in-vitro and in-vivo safety and efficacy data have demonstrated that SnapShot enables drug developers to produce very high concentration, subcutaneous formulations of novel mAbs and biologics. Surf Bio was launched by the founders of Bigfoot Biomedical and AGC to commercialize a breakthrough drug delivery technology developed in the Appel lab at Stanford University. For more information about Surf Bio, visit www.surf.bio.
Contact for Surf Bio:Tiberend Strategic Advisors, Inc.
Eric Reiss
[email protected]
SOURCE Surf Bio, Inc.
